Invitation to Roche’s Virtual Immunology/SLEuro Investor Event
2026-02-17
 We are pleased to invite investors and analysts to participate in our virtual event on Monday, 9 March 2026, to highlight Roche’s immunology kidney pipeline and data from the Phase III ALLEGORY study evaluating Gazyva (obinutuzumab) in systemic lupus erythematosus (SLE), which will be presented at the15th European Lupus Meeting (SLEuro) March 6th 2026. 17:00 - 18:00 CET / 16:00 - 17:00 GMT 12:00 - 1:00 pm EDT / 9:00 - 10:00 am PDT Agenda Introduction Bruno Eschli, Head of Investor Relations Immunology kidney pipeline update Jay Garg, VP Global Franchise Head of Nephrology Ph III (ALLEGORY) Gazyva in SLE Richard A. Furie, MD, Chief, Division of Rheumatology, Northwell Health, Marilyn and Barry Rubenstein Chair in Rheumatology and Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Q&A The slides will be available for download at 16:00 CET on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice |
| Best regards, Bruno Eschli Head of Investor Relations | Sabine Borngräber Investor Relations Officer |
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.